FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026565579> ?p ?o ?g. }

• W3026565579 abstract "Abstract Background Deficits in social functioning are a core feature of schizophrenia and may be due to the interaction of multiple factors including negative symptoms, depression symptoms, and deficits in social cognition. Social and functional impairment in schizophrenia can be difficult to treat, may not correlate with improvements in psychotic symptoms, and has been associated with poor long-term patient outcomes. Lumateperone (lumateperone tosylate, ITI-007) is a mechanistically novel agent for the treatment of schizophrenia that simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. Lumateperone was shown to be efficacious and well tolerated in 2 acute placebo-controlled studies and its safety and effectiveness was further supported in a long-term open-label study. The effects of lumateperone 42 mg (ITI-007 60 mg) on schizophrenia symptoms associated with social function were investigated in a post hoc analysis of a study that included risperidone 4 mg as an active control (Study 005, NCT01499563). Symptoms associated with social functioning were assessed with the Positive and Negative Syndrome Scale (PANSS)-derived Prosocial factor (PANSS items P3, P6, N2, N4, N7, G16), which has been utilized previously to evaluate the efficacy of various antipsychotics on this functional domain. Methods This is a post hoc analysis of data from a positive placebo- and active-controlled study in patients with an acute exacerbation of schizophrenia. Change from baseline in the PANSS Prosocial factor was assessed in the intent-to-treat (ITT) population and in patients with prominent negative symptoms (PNS, score ≥4 on at least 3 negative symptom items) or moderate-to-severe depression symptoms (Calgary Depression Scale for Schizophrenia [CDSS] ≥6) at baseline. Inferential analysis was conducted using a mixed-effects model for repeated measures (MMRM). Results The ITT population comprised 231 patients (placebo, n=80; lumateperone 42 mg, n=76; risperidone 4 mg, n=75); the PNS and CDSS ≥6 populations comprised 110 and 54 patients, respectively. Lumateperone 42-mg treatment was associated with significantly greater improvement compared with placebo on the PANSS Prosocial factor (least-squares mean difference [LSMD] vs placebo = −2.7; P&lt;.001). Risperidone also was superior to placebo on the PANSS Prosocial factor (LSMD= −1.8; P=.011). Similar treatment effects for lumateperone 42 mg were seen on the PANSS Prosocial factor in patients with PNS at baseline (LSMD −2.6, P=.006). Conversely, in patients with PNS, risperidone treatment showed small and non-significant treatment effects on the PANSS Prosocial factor (LSMD= −0.4; P=.707). In patients with moderate-to-severe depression symptoms at baseline, marked and significant improvements on the PANSS Prosocial factor were seen in lumateperone-treated patients (LSMD= −4.9; P&lt;.001) but not in risperidone-treated patients (LSMD=−1.3; P=.397). Discussion Lumateperone 42 mg significantly improved schizophrenia symptoms related to social functioning. In contrast to risperidone, lumateperone was associated with similar or greater treatment effects on the PANSS Prosocial factor in patients with prominent negative symptoms or moderate-to-severe depression symptoms at baseline. These results suggest that lumateperone may have benefits on schizophrenia symptoms associated with social function." @default.
• W3026565579 created "2020-05-29" @default.
• W3026565579 creator A5001023467 @default.
• W3026565579 creator A5024297999 @default.
• W3026565579 creator A5029742430 @default.
• W3026565579 creator A5030800916 @default.
• W3026565579 creator A5033804720 @default.
• W3026565579 creator A5039397245 @default.
• W3026565579 creator A5079640166 @default.
• W3026565579 date "2020-04-01" @default.
• W3026565579 modified "2023-10-17" @default.
• W3026565579 title "S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL" @default.
• W3026565579 doi "https://doi.org/10.1093/schbul/sbaa031.287" @default.
• W3026565579 hasPublicationYear "2020" @default.
• W3026565579 type Work @default.
• W3026565579 sameAs 3026565579 @default.
• W3026565579 citedByCount "0" @default.
• W3026565579 crossrefType "journal-article" @default.
• W3026565579 hasAuthorship W3026565579A5001023467 @default.
• W3026565579 hasAuthorship W3026565579A5024297999 @default.
• W3026565579 hasAuthorship W3026565579A5029742430 @default.
• W3026565579 hasAuthorship W3026565579A5030800916 @default.
• W3026565579 hasAuthorship W3026565579A5033804720 @default.
• W3026565579 hasAuthorship W3026565579A5039397245 @default.
• W3026565579 hasAuthorship W3026565579A5079640166 @default.
• W3026565579 hasBestOaLocation W30265655791 @default.
• W3026565579 hasConcept C118552586 @default.
• W3026565579 hasConcept C126322002 @default.
• W3026565579 hasConcept C142724271 @default.
• W3026565579 hasConcept C15744967 @default.
• W3026565579 hasConcept C204787440 @default.
• W3026565579 hasConcept C27081682 @default.
• W3026565579 hasConcept C2776412080 @default.
• W3026565579 hasConcept C2777014857 @default.
• W3026565579 hasConcept C2779727114 @default.
• W3026565579 hasConcept C2780057945 @default.
• W3026565579 hasConcept C2780135775 @default.
• W3026565579 hasConcept C2908647359 @default.
• W3026565579 hasConcept C67761136 @default.
• W3026565579 hasConcept C70410870 @default.
• W3026565579 hasConcept C71924100 @default.
• W3026565579 hasConcept C99454951 @default.
• W3026565579 hasConceptScore W3026565579C118552586 @default.
• W3026565579 hasConceptScore W3026565579C126322002 @default.
• W3026565579 hasConceptScore W3026565579C142724271 @default.
• W3026565579 hasConceptScore W3026565579C15744967 @default.
• W3026565579 hasConceptScore W3026565579C204787440 @default.
• W3026565579 hasConceptScore W3026565579C27081682 @default.
• W3026565579 hasConceptScore W3026565579C2776412080 @default.
• W3026565579 hasConceptScore W3026565579C2777014857 @default.
• W3026565579 hasConceptScore W3026565579C2779727114 @default.
• W3026565579 hasConceptScore W3026565579C2780057945 @default.
• W3026565579 hasConceptScore W3026565579C2780135775 @default.
• W3026565579 hasConceptScore W3026565579C2908647359 @default.
• W3026565579 hasConceptScore W3026565579C67761136 @default.
• W3026565579 hasConceptScore W3026565579C70410870 @default.
• W3026565579 hasConceptScore W3026565579C71924100 @default.
• W3026565579 hasConceptScore W3026565579C99454951 @default.
• W3026565579 hasLocation W30265655791 @default.
• W3026565579 hasLocation W30265655792 @default.
• W3026565579 hasOpenAccess W3026565579 @default.
• W3026565579 hasPrimaryLocation W30265655791 @default.
• W3026565579 hasRelatedWork W11075747 @default.
• W3026565579 hasRelatedWork W3978893 @default.
• W3026565579 hasRelatedWork W4930954 @default.
• W3026565579 hasRelatedWork W510232 @default.
• W3026565579 hasRelatedWork W5204776 @default.
• W3026565579 hasRelatedWork W6314525 @default.
• W3026565579 hasRelatedWork W889026 @default.
• W3026565579 hasRelatedWork W9867636 @default.
• W3026565579 hasRelatedWork W3117079 @default.
• W3026565579 hasRelatedWork W9724497 @default.
• W3026565579 isParatext "false" @default.
• W3026565579 isRetracted "false" @default.
• W3026565579 magId "3026565579" @default.
• W3026565579 workType "article" @default.